Roche posts 'impressive' TIGIT combo lung cancer data, but trial deaths weigh down on shares Moderna, hoping to prove it's no one-trick COVID pony, posts early peek at mRNA flu shot hopeful Novartis poaches Roche's neuro and rare disease R&D lead, replacing Shanker Eli Lilly pens $1.5B biobucks pact with China's Regor for metabolic disease work Albireo CMO Horn is out the door 5 months after US, EU approvals of rare liver disease drug Chan Zuckerberg Initiative to pour $3.4B over 10 years into AI, imaging and other tech to unravel biomedical challenges ALS organizations call for Senate to follow House's suit in passing $500M R&D bill Amid Aduhelm's rocky launch, Biogen eyes large-scale layoffs: report Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments Fierce Pharma Asia—China's new NRDL; Biocon-Viatris biosimilar merger?; Avistone's $200M series A Chutes & Ladders—Former FDA leader Hahn lands at cancer blood test maker Harbinger Health Featured Story | By Ben Adams New follow-up data for Roche’s Tecentriq-tiragolumab combination therapy in certain lung cancer patients have analysts sighing in relief that the anti-TIGIT element appears to be pulling its weight. read more |
| |
|---|
|
Top Stories By Ben Adams Moderna is set to make tens of billions of dollars this year and next from its mRNA COVID vaccine and booster, but the market won’t let the Big Biotech rest on its laurels and wants broader applicability from its programs. read more By Ben Adams Novartis has been busy selling off its stake in Roche but quietly this month also got a little extra from its fellow Swiss native after nabbing Bob Baloh, M.D., Ph.D., to run its growing neuroscience division. read more By Ben Adams Eli Lilly is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to seek out, develop and hopefully sell new therapies for metabolic disorders. read more By Kyle LaHucik After 3.5 years and oversight of approvals in the U.S. and Europe for its rare liver disease drug, Bylvay, Pat Horn is out as chief medical officer of Albireo Pharma. He notified the Boston biopharma last week that he'd leave by the end of the year for another opportunity. read more By Andrea Park Five years into its lofty goal of funding projects to “cure, prevent or manage all disease within our children’s lifetime,” the Chan Zuckerberg Initiative’s Biohub is getting a major boost. read more By Kyle LaHucik After the U.S. House of Representatives overwhelmingly passed a bill that would grant $500 million to ALS research, three organizations called on the Senate to swiftly follow suit. The muscle-wasting disease has befuddled researchers and drug developers for decades. read more By Fraiser Kansteiner After the rocky launch of its controversial Alzheimer’s disease drug Aduhelm, Biogen is gearing up for layoffs, STAT News reports. Overall, the staff squeeze could slash expenses by $500 million to $750 million, STAT said. read more By Kyle LaHucik University of Chicago researchers say their novel nanomedicine shrank vascular lesions in mice and stopped the progression of plaque buildup that leads to vascular diseases. The team is working to secure funding for a larger animal study and form a company to test the treatment in people. read more By Angus Liu Big Pharma's cancer immunotherapies were once again excluded from China's national reimbursement. Biocon and Viatris are reportedly considering combining their biosimilar operations. A Chinese oncology biotech just secured a handsome $200 million series A. And more. read more By Kyle LaHucik Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator's blood cancer test startup Harbinger Health. Takeda's oncology leader Rachael Brake heads to Corbus as chief scientific officer charged with redefining scope of early-stage pipeline. Goldfinch Bio snags 13-year Ardelyx vet as CSO. read more Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored By: BBK Worldwide Create more inclusive clinical trials, enroll them faster, and keep participants engaged longer with the latest Study Voices survey results and insights. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce BD&L Summit March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event | 